Erlotinib is an inhibitor of EGFR and has been approved to treat non-small cell lung and pancreatic cancers and was shown to exert multifarious antineoplastic effects in glioblastoma in preclinical studies (70, 71). This evidence concerns the gene EGFR and glioblastoma.